Positive Influence of 177Lu PSMA-617 Therapy on Bone Marrow Depression Caused by Metastatic Prostate Cancer

Clin Nucl Med. 2016 Jun;41(6):478-80. doi: 10.1097/RLU.0000000000001195.

Abstract

A 75-year-old man with castrate-resistant prostate cancer and increasing prostate-specific antigen (PSA) level developed severe bone marrow depression during Ra radionuclide therapy. Because of this, he was treated with Lu-PSMA in compassionate use for this not-yet-approved therapy. At the beginning of Lu-PSMA therapy, repeated blood transfusions (BT) were necessary. Six months after the last BT, after 3 cycles of Lu-PSMA, his blood count stabilized. He required no further BTs and his PSA level remained lowered.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anemia / chemically induced
  • Anemia / drug therapy
  • Antineoplastic Agents / adverse effects
  • Bone Marrow Diseases / chemically induced
  • Bone Marrow Diseases / drug therapy*
  • Bone Neoplasms / diagnostic imaging
  • Bone Neoplasms / drug therapy*
  • Bone Neoplasms / secondary
  • Compassionate Use Trials
  • Dipeptides / therapeutic use*
  • Edetic Acid / analogs & derivatives
  • Gallium Radioisotopes
  • Heterocyclic Compounds, 1-Ring / therapeutic use*
  • Humans
  • Male
  • Oligopeptides
  • Positron Emission Tomography Computed Tomography
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms, Castration-Resistant / blood
  • Prostatic Neoplasms, Castration-Resistant / drug therapy*
  • Prostatic Neoplasms, Castration-Resistant / pathology
  • Radioisotopes / adverse effects
  • Radionuclide Imaging
  • Radiopharmaceuticals
  • Radium / adverse effects
  • Technetium Tc 99m Medronate

Substances

  • 177Lu-PSMA-617
  • Antineoplastic Agents
  • Dipeptides
  • Gallium Radioisotopes
  • Heterocyclic Compounds, 1-Ring
  • Oligopeptides
  • Radioisotopes
  • Radiopharmaceuticals
  • gallium 68 PSMA-11
  • Edetic Acid
  • Prostate-Specific Antigen
  • radium Ra 223 dichloride
  • Radium
  • Technetium Tc 99m Medronate